Oracle Corp. is lending its expertise to help the U.S. government run clinical trials on two malaria drugs to gauge their effectiveness in treating COVID-19, the respiratory disease caused by the coronavirus.

The New York Times said Oracle was currently in talks with the White House about providing a “platform” for the testing.

Officials are still working out the details, but the plans seems to be that the Department of Health and Human Services, Food and Drug Administration and Centers for Medicare and Medicaid will use it to analyze how the drugs perform when administered to COVID-19 patients.

U.S. President Donald Trump has been enthusiastic about the potential of the malaria drugs chloroquine and hydroxychloroquine in treating the disease. There has been some anecdotal evidence that the drugs can help to reduce the severity of symptoms, but more testing is required before any official treatment can be sanctioned.

Oracle’s platform would reportedly be used to track treatments, store information on their effectiveness and collect any additional data that might be useful for researchers.

The New York Times said the data would be critical for researchers trying to determine the effectiveness of chloroquine and hydroxychloroquine. The drugs have already been used on some patients, but only on a largely “uncontrolled basis,” the report added.

Photo: Leo2014/Pixabay